Introduction
============

Papillary thyroid cancer (PTC) is the most common type of well-differentiated thyroid cancer ([@b1-etm-0-0-5087]). Primary lymph node metastasis (LNM) occurs in approximately 30--40% of cases, and microscopic involvement of the lymph nodes may occur in as high as 80--90% ([@b2-etm-0-0-5087]). LNM is an important risk indicator of locoregional recurrence, and regional LNM could be the second most important independent prognostic indicator ([@b3-etm-0-0-5087]--[@b5-etm-0-0-5087]). Identifying the characteristics of PTCs for invasion and metastasis, is helpful for clinicians to assesse the risk of recurrent disease and to provide a personalized therapy for each patient. Patients with PTC have good prognosis after successfully personalized management, with the reported 10-year survival rate recorded at 93% ([@b6-etm-0-0-5087]). Recent researches have focused on how to reduce excess therapy and screen high-risk patients ([@b7-etm-0-0-5087],[@b8-etm-0-0-5087]). Fine needle aspiration (FNA) is an important diagnostic tool in the evaluation of thyroid nodules. The 2015 ATA guidelines strongly recommend FNA for nodules that appear suspicious during ultrasound (US) ([@b9-etm-0-0-5087]). However, FNA cannot provide accurate evaluation of tumor features for invasion and metastasis. Even though the expression of genes in PTCs involved in tumor angiogenesis and metastasis has been investigated recently ([@b10-etm-0-0-5087],[@b11-etm-0-0-5087]), the main constraint on its clinical application is the high cost. It is necessary to establish a more promising diagnostic modality concerning optimization of cost-effectiveness and perioperative prediction of lymph nodes clearance.

LNM in PTCs usually occurs initially in the central cervical lymph node compartment ahead of the lateral compartment, in spite of their occasional skip to the lateral compartment, leaving the central compartment tumor-free ([@b12-etm-0-0-5087],[@b13-etm-0-0-5087]). US has been widely used for preoperative staging in patients with PTC to determine the necessary extent of surgery. Yet, LNM in the central neck may not appear abnormal on preoperative US detection, the ability of preoperative US to identify central neck LNM is limited ([@b14-etm-0-0-5087]). Therefore, a growing number of researchers are advocating prophylactic central lymph node dissection (CLND) for PTC patients staging cN0 (AJCC/UICC TNM, 7th edition, as proposed by the College of American Pathologists) based on a preoperative US or upon cervical palpation ([@b15-etm-0-0-5087],[@b16-etm-0-0-5087]). However, controversy whether prophylactic CLND has major impact on disease-specific survival still exists ([@b17-etm-0-0-5087]). Prophylactic CLND might benefit greatly if PTC patients with high risk of LNM can be screened preoperatively. Tumor angiogenesis or neovascularization is accepted as an indicator of tumor growth and metastasis ([@b18-etm-0-0-5087]--[@b20-etm-0-0-5087]). A recent study demonstrated higher blood supply is associated with regional LNM of PTC ([@b21-etm-0-0-5087]), while studies of microvascular density (MVD) have generated a conflicting hypothesis that recurrent thyroid cancers expressed less intratumoral microvessels ([@b22-etm-0-0-5087]). Given that by providing visualization of the macro- and microvascularization of the tumor, contrast-enhanced US (CEUS) can evaluate thyroid tumors qualitatively and quantitatively. Though some studies have evaluated the value of CEUS in the diagnosis of thyroid malignant nodules ([@b23-etm-0-0-5087],[@b24-etm-0-0-5087]), there are few studies available assessing CEUS to help risk-stratify PTC patients with LNM. In this study we investigated the clinical implications of CEUS in PTCs, and examined the relation between enhancements of PTC and the risk of LNM.

Patients and methods
====================

### Patients

The present study\'s design and protocol were approved by the Ethics Committee of the Third People\'s Hospital of Chengdu (Sichuan, China) and all study subjects signed an informed consent. A retrospective analysis of prospectively collected data was performed, from May 2014 to November 2016, based on 42 patients candidate to surgery for suspicious PTCs. Subjects with the following US-based detection criteria were included: suspicious PTCs including sonographic findings: solid hypoechoic, long/short ratio \<2, poorly defined margin, and microcalcifications. The exclusion criteria were: i) a nodule with a fluid content \>50% of volume; ii) the presence of a coarse calcification inside a nodule; iii) insufficient normal thyroid tissue around the target nodule; iv) any condition of hyperthyroidism; v) pregnancy; vi) heart failure and vii) severe pulmonary hypertension ([@b25-etm-0-0-5087]). The study population that was enrolled for investigation comprised a total of 42 individuals, including 33 women and 9 men (mean age, 49.1 years; range, 22--73 years; SD ± 13.5 years). The individuals were advised that any surgical procedure would not be influenced by participation in the present study.

### CEUS

Once enrolled in the study, the individuals underwent CEUS with conventional US by 2 experienced radiologists 3 days before any surgical intervention, using an IU Elite scanner (Phillips Medical Systems, Bothell, WA, USA), equipped with an L12-5 transducer. Initially, the 3 dimensions of the nodules were measured by US, and the largest diameter was recorded as the nodule size. CEUS was performed to examine the mass or suspicious region. Under the US contrast mode the mechanical index (MI) ranged between 0.06 and 0.08, and the focal point was adjusted to the middle or the lower edge of the thyroid nodules. Double-contrast mode was used to ensure the probe was in parallel with the long axis of the thyroid gland as much as possible. If there were multifocal lesions, the most suspicious lesion was taken for analysis. The contrast medium was obtained by adding 5 ml of physiological saline to SonoVue (Bracco SpA, Milan, Italy). Once the largest plane of the lesion in long axis was selected, a contrast bolus of 2.4 ml was injected manually via a 20-gauge intravenous cannula placed in an antecubital vein, and 5 ml of normal saline followed as a flush. Meanwhile, the timer on the US system was started, and the imaging plane was kept as stable as possible. Each contrast imaging acquisition lasted ≥3 min after bolus injection and was digitally stored. The imaging data obtained from CEUS were continuously stored. All individuals were monitored for adverse events until 20 min after the procedure. The offline analysis was performed with dedicated software (Q-LAB^®^; Philips Medical Systems, The Netherlands). In each case, based upon CEUS, signal intensity changes of the nodule were measured in decibels (dB). A region of interest (ROI) was traced out along the edge of the nodule, and another ROI of similar size on the peripheral thyroid parenchyma ([Fig. 1](#f1-etm-0-0-5087){ref-type="fig"}). Quantitative perfusion parameters were obtained using the ROI method and time-intensity curves, including baseline signal intensity (BI, dB), Time of enhancement beginning (TEB, sec), time to peak (TP, sec), peak accelerating time (PAT, sec), peak intensity (PI, dB), mean intensity (MI, dB), intensity increase velocity (IIV, dB/sec), and intensity decrease velocity (IDV, dB/sec).

### US-guided FNA

Based on CEUS and US imaging, preoperative US-guided FNA was performed to confirm the cytological diagnosis in 42 cases. The FNA procedure was carried out using a standard 21 gauge needle. Sampling typically targets the solid component of the lesion. If there was more than one nodule, a sample was taken from the nodule with suspicious or atypical US characteristics. The cytopathological system used in the present study was the Bethesda system.

### Surgery

The surgical approach at our hospital was as follows: i) Total thyroidectomy (TT) with prophylactic CLND in cases of PTCs with bilateral nodularity and without suspected central neck and/or lateral cervical LNM on US; ii) TT with neck dissection of involved compartments in cases of PTCs with any of following features: suspected central neck and/or lateral cervical LNM on US, cervical LNM confirmed by positive frozen section, extrathyroidal extension, tumor \>4 cm; iii) lobectomy + isthmusectomy (LI) with prophylactic CLND in cases of PTCs without any of following features: contralateral lesions, suspected central neck and/or lateral cervical LNM on US, cervical LNM confirmed by frozen section, extrathyroidal extension.

Demographic data on patient clinical features (sex, age at diagnosis) as well as histological characteristics of tumors and neck lymph samples (size of tumors, lesion locations, extrathyroidal extension) were recorded. All thyroid and lymph node specimens were evaluated by the same pathologist (with 10 years working experience).

### MVD measurements

Measurements of MVD were performed independently by the same one pathologist mentioned above, who was blinded to the US findings. Formalin-fixed paraffin-embedded tissues were segmented at 3--4 µm thick sections using a semi-automatic microtome. Consecutive sections were placed on slides pre-coated with egg albumin for routine hematoxylin and eosin staining and on slides coated with poly-L-lysine for immunohistochemical staining for CD34 (a mouse antihuman CD34 monoclonal antibody (W-0117; Dako Corporation, Carpinteria, USA) was used. Completed according to the method by Weidner *et al* ([@b26-etm-0-0-5087]), regions with the highest vessel density ('hot spots') were located by scanning the tissue sections under ×10-power microscope. Three different fields were randomly chosen within each hot spot, and individual microvessels were manually outlined using freehand draw option in Image Pro Plus software 7.0 (Media Cybernetics, Inc. Singapore, Singapore) and counted under ×40-power power. Images of these selected fields along with the marked microvessels were captured. The mean average scores were tabulated and used for statistical analysis.

### Statistical analysis

The SPSS 22.0 software package (IBM, Armonk, NY, USA) was used for statistical analysis. Values are expressed as the mean ± SD. Categorical variables were analyzed by Fisher\'s exact test. Continuous variables were compared between groups using the t-test and analysis of variance. Spearman correlation analysis was used to analyze correlation between quantitative variables and LNM. Diagnostic performance was estimated by ROC analysis. A P\<0.05 was statistically significant.

Results
=======

FNA biopsy yielded positive and non-diagnostic results in 39 and 3 patients, respectively, of these 3 patients. Two of the 3 un-diagnostic exhibited extremely weak enhancements on CEUS, while the other a homogeneous hyper-enhancement. Both the enhancement patterns were suggestive of benign, which was ultimately confirmed by surgery. CEUS misdiagnosed 2 PTCs as benign nodules, and 1 subacute thyroiditis as PTC. The sensitivity, specificity and accuracy of CEUS for PTCs suspected by conventional US was 97.4, 75.0, and 95.2%, respectively.

A total of 39 cases were confirmed as PTC by surgery. They were divided into two groups: LNM^+^ group (PTCs with LNM, 27 cases) and LNM^−^ group (PTCs without LNM, 12 cases). [Table I](#tI-etm-0-0-5087){ref-type="table"} demonstrates that compared with LNM^−^ group, patients in LNM^+^ group had a significantly younger age (P\<0.05) and larger mean tumor size (P\<0.05). It was also shown that patients ≤45 years old (P\<0.05), tumors \>10 mm in size (P\<0.05) and capsular infiltration (P\<0.05) were more commonly seen in LNM^+^ group.

CEUS enhancements in early ascending phases was classified into the following two new patterns for the first time ([Fig. 2](#f2-etm-0-0-5087){ref-type="fig"}). The first pattern was early partial hyper-enhancement, presenting either complex enhancement (characterized by periphery hyperperfused with relatively central hypoperfused; [Fig. 2A](#f2-etm-0-0-5087){ref-type="fig"}) or pervasive heterogeneous hyper-enhancement ([Fig. 2B](#f2-etm-0-0-5087){ref-type="fig"}). The sencond pattern, non hyper-enhancement, including centripetal hypo-enhancement ([Fig. 2C](#f2-etm-0-0-5087){ref-type="fig"}) and iso-enhancement ([Fig. 2D](#f2-etm-0-0-5087){ref-type="fig"}), both of which were heterogeneous. It was demostrated that, from late ascending to descending phases, PTC lesions mainly presented hypo-enhancement, no stastical differences were found between the two goups. [Table II](#tII-etm-0-0-5087){ref-type="table"} demonstrates that, the ratio of the first enhancement pattern was significantly higher in LNM^+^ group than that in LNM^−^ group (P\<0.01), while the second enhancement pattern was proportionately lower in LNM^−^ group than that in LNM^+^ group (P\<0.01). Time-intensity curves analysis indicated that MI, IIV and mean intensity ratio of intratumoral/peripheral thyroid parenchyma (MIR) were significantly higher in LNM^+^ group than that in LNM^−^ group (all P\<0.05), suggesting higher and faster enhancements were more common during early ascending period in LNM^+^ group. In addition, the measurements of MVD by CD34 expression detection demonstrated that, both intratumoral MVD and MVD ratio of intratumoral/peripheral thyroid parenchyma (MVDR) were higher in LNM^+^ group than that in LNM^−^ group (P\<0.01) ([Fig. 3](#f3-etm-0-0-5087){ref-type="fig"}). As regards the Spearman correlation analysis, MI (*r*=0.11, P=0.48), IIV (*r*=0.09, P=0.35), MVDR (*r*=0.57, P\<0.05) and MIR (*r*=0.41, P\<0.05) was positively correlated with LNM. The ROC analysis (AUC = 0.74, P\<0.05) revealed the MIR of 0.86 was the optimal threshold of LNM in PTCs ([Fig. 4](#f4-etm-0-0-5087){ref-type="fig"}).

Discussion
==========

ATA 2015 recommended that, FNA is the accepted standard tool for the evaluation of thyroid nodules, as it is reported to be safe and accurate ([@b9-etm-0-0-5087]). Definitely, FNA does have limitations, which include a significant rate of non-diagnostic results ranging from 0.6 to 43.1% ([@b27-etm-0-0-5087],[@b28-etm-0-0-5087]). In total, 7.1% (3/42) of undiagnosis by FNA were shown in our study. The three cases undiagnosed by FNA alone were diagnosed as benign via combined use of FNA with CEUS, two cases were confirmed for nodular goiter and one for follicular adenoma by surgery ultimately. Nodules of nodular goiter are prone to hemorrhage appearing initially nonechogenic on US. When the blood converts from a liquid state to a solid state, the nonechogenic turns into solid-like hypoechogenic. When US-guided FNA targeted the solid-like hypoechogenic lesions, it\'s difficult to obtain adequate cellular content. While previous hemorrhage exhibits extremely low enhancement, no enhancement or local non-enhancement, CEUS may prove to be useful in distinguishing solid-like lesions from true solidary nodules. It is well known that, capsular or vesicular invasion cannot be detected by FNA cytology, so the accuracy of FNA has been largely compromised for follicular lesions, namely follicular thyroid carcinoma (FTC) and follicular adenoma (FA). CEUS could provide information of microvascular features in a whole profile for a follicular lesion. It might be one of the possible reasons why the case of follicular adenoma was diagnosed as benign on preoperative CEUS accurately. On the other hand, CEUS misdiagnosed 2 cases of PTC with iso-enhancement as benign nodules, and 1 case of subacute thyroiditis with hypo-enhancement as PTC. CEUS was highly sensitive and accurate in diagnosis of PTC in our study. Its low specificity meant CEUS could not be recommended as a first-line investigation, but a supplement to increase the preoperative diagnostic accuracy of FNA.

LNM is common for PTC patients. Although there is still controversy on the prognosis of LNM, it is universally accepted that cervical LNM should be removed ([@b29-etm-0-0-5087],[@b30-etm-0-0-5087]). Central cervical lymph nodes are easily covered by the thyroid gland, and micro-metastasis of lymph nodes is difficult to detect, so the ability of preoperative US to identify central neck LNM is limited ([@b31-etm-0-0-5087]). Besides, preoperative US showed a medium sensitivity and a relatively high diagnostic accuracy in detecting lateral neck LNM ([@b32-etm-0-0-5087]). If PTC patients at high risk of LNM identified preoperatively, they may benifit from extended resection and lymph nodes dissection. For patients with low risk of LNM, conservative treatment with regular monitoring may probably help avoid unnecessary prophylactic CLND and reduce the overall financial costs. Several studies have explored the value of CEUS in the diagnosis of PTC ([@b23-etm-0-0-5087],[@b31-etm-0-0-5087]), however, the application of CEUS of PTC lesions for predicting the risk of LNM has not been reported. The present study compared clinical and pathological characteristics between PTCs with and without LNM, the results showed that LNM^+^ group had a relatively younger mean age and larger mean tumor size compared to LNM^−^ group. Besides, LNM^+^ group had a higher incidence of patients ≤45 years old, tumors \>10 mm in size and capsular infiltration. These findings which were similar to previous studies ([@b33-etm-0-0-5087],[@b34-etm-0-0-5087]), suggest that age (≤45 years old), larger primary tumor size, and the presence of capsular infiltration indicate an increased risk of LNM in PTC.

Studies have shown that, PTC lesions exhibit lower enhancement than benign thyroid nodules on CEUS. As a result of thyroid tumor neovascularization, pathological vessels differ significantly from normal vessels. The lack of muscle and nerve support, vascular dysfunction and tortuosity may lead to low enhancement of the contrast agent ([@b35-etm-0-0-5087],[@b36-etm-0-0-5087]). The present study, for the first time, investigated differences between PTC patients with and without LNM using qualitative and quantitative CEUS. In the present study, PTC lesions mainly presented hypo-enhancement from late ascending to descending phases, no stastical differences were found between PTCs with and without LNM. Yet in early ascending period, enhancements were divided into two patterns (partial hyper-enhancement pattern and non hyper-enhancement pattern) as mentioned in the Results section. By using the newly introduced classification, the ratio of the first pattern in LNM^+^ group was significantly higher than that in LNM^−^ group, supporting the hypothesis that local higher blood supply may be associated with LNM ([@b21-etm-0-0-5087]). It was revealed that patients in LNM^+^ group had a higher and faster enhancement at early contrast agent ascending period, and had significantly higher MVD than that in LNM^−^ group. PTCs with LNM have been reported to be associated with high expression of vascular proliferative factors, for example vascular growth factor A (VEGF-A) ([@b35-etm-0-0-5087]). The lymphatic vessel density (LVD), which is directly involved with LNM, is most likely connected to VEGF stimulation ([@b36-etm-0-0-5087],[@b37-etm-0-0-5087]). Besides, VEGF and MVD have significant relationship in assessing microvascular angiogenesis in thyroid carcinomas. Given all that, MVD could be correlated with LNM of PTC ([@b38-etm-0-0-5087]). Since several studies reported that, quantification of CEUS can be applied to assess MVD in PTC tissues ([@b37-etm-0-0-5087],[@b38-etm-0-0-5087]), CEUS can be recognized as a cost-effective tool for visualizing MVD of PTC. It was investigated that higher local concentrations of microbubbles was observed in PTC lesions with LNM than that without LNM, consistent with the fact that LNM might rely on local rich blood supply. For PTC patients of this study, patial hyper-enhancement on CEUS was speculated to be associated with increased risk of LNM. MIR on quantitative CEUS was positive correlated with LNM in PTC, instead of other quantitative parameters such as MI, IIV, and IDV. The MIR of 0.86 was the optimal threshold of LNM in PTCs. Further researches on a larger population is needed to identify the threshold accurately and help risk-stratify PTC patients with LNM.
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![ROI and time-intensity curves in a PTC lesion (red tracing) and the PTC (yellow tracing), respectively. ROI, region of interest; PTC, papillary thyroid carcinoma.](etm-14-05-4321-g00){#f1-etm-0-0-5087}

![Patterns in early ascending phases of contrast-enhanced ultrasonography. (A) Complex enhancement, manufesting periphery hyperperfused (arrow) with relatively central hypofused (triangle) in a PTC patient with LNM. (B) Pervasive heterogeneous hyper-enhancement (arrow) in a PTC patient with LNM. (C) Centripetal hypo-enhancement (arrow) in a PTC patient without LNM. (D) Iso-enhancement pattern (arrow) in a PTC patient without LNM. PTC, papillary thyroid carcinoma; LNM, lymph node metastasis.](etm-14-05-4321-g01){#f2-etm-0-0-5087}

![(A and B) CD34 immunohistochemical analysis. Vascular endothelial cells stained brown, ×100-power microscope, showing an increase expression of CD34 in a PTC lesion with LNM (B) than that in a PTC lesion without LNM (A). PTC, papillary thyroid carcinoma. LNM, lymph node metastasis.](etm-14-05-4321-g02){#f3-etm-0-0-5087}

![ROC analysis for MIR of intratumoral/peripheral thyroid parenchyma. The area under the ROC curve: 0.74, P\<0.05. MIR, mean intensity ratio; ROC, receiver operating characteristic.](etm-14-05-4321-g03){#f4-etm-0-0-5087}

###### 

Comparison of clinicopathological characteristics between LMN^+^ group and LMN^−^group.

  Variables                          LMN^+^ group (n=27) (%)   LMN^−^ group (n=12) (%)   P-value
  ---------------------------------- ------------------------- ------------------------- -----------------------------------------------------
  Age (years)                                                                            0.012^[a](#tfn1-etm-0-0-5087){ref-type="table-fn"}^
    ≤45                              21 (77.8)                 4 (33.3)                  
    \>45                             6 (22.2)                  8 (66.7)                  
  Mean age (years)                   41.5±16.1                 49.3±15.8                 0.047^[a](#tfn1-etm-0-0-5087){ref-type="table-fn"}^
  Sex                                                                                    0.690
    Male                             7 (25.9)                  2 (16.7)                  
    Female                           20 (74.1)                 10 (83.3)                 
  Tumor size (mm)                                                                        0.041^[a](#tfn1-etm-0-0-5087){ref-type="table-fn"}^
    ≤10                              8 (29.6)                  8 (66.7)                  
    \>10                             19 (70.4)                 4 (33.3)                  
  Mean size (mm)                     28.1±10.7                 10.5±3.6                  0.039^[a](#tfn1-etm-0-0-5087){ref-type="table-fn"}^
  Right lobe lesion                  13 (48.1)                 7 (58.3)                  0.631
  Left lobe lesion                   6 (22.2)                  2 (16.7)                  
  Multiplicity and/or bilaterality   8 (29.7)                  3 (25.0)                  
  Capsular infiltration (%)          17 (62.9)                 3 (25.0)                  0.041^[a](#tfn1-etm-0-0-5087){ref-type="table-fn"}^
  Location of the malignancy                                                             0.720
    Upper third                      9 (33.3)                  5 (41.6)                  
    Mid and lower third              18 (66.7)                 7 (58.4)                  

P\<0.05. LMN^+^ group, PTC with LNM. LMN^−^ group, PTC without LNM. PTC, papillary thyroid carcinoma; LNM, lymph node metastasis.

###### 

Comparison of CEUS enhancement characteristics and MVD features between between LMN^+^ group and LMN^−^ group.

  Characteristic                                                             LMN^+^ group (n=27) (%)   LMN^−^ group (n=12) (%)   P-value
  -------------------------------------------------------------------------- ------------------------- ------------------------- -----------------------------------------------------
  Enhancement type                                                                                                               
  Early partial hyper-enhancement                                            22 (81.5)                 3 (25.0)                  0.001^[a](#tfn2-etm-0-0-5087){ref-type="table-fn"}^
    Complex enhancement                                                      17                        0                         
    Pervasive                                                                                                                    
    Hyper-enhancement                                                        5                         3                         
  Non hyper-enhancement                                                      5 (18.5)                  9 (75.0)                  
    Centripetal                                                                                                                  
    Hypo-enhancement                                                         5                         8                         
    Iso-enhancement                                                          0                         1                         
  Mean intensity (MI, dB)                                                    7.7±4.9                   6.4±3.2                   0.033^[b](#tfn3-etm-0-0-5087){ref-type="table-fn"}^
  Intensity increase velocity (IIV, dB/sec)                                  1.7±0.8                   1.6±0.9                   0.019^[b](#tfn3-etm-0-0-5087){ref-type="table-fn"}^
  Intensity decrease velocity (IDV, dB/sec)                                  1.3±0.5                   1.2±0.3                   0.221
  Mean intensity ratio of Intratumoral/peripheral thyroid parenchyma (MIR)   0.89±0.19                 0.82±0.33                 0.045^[b](#tfn3-etm-0-0-5087){ref-type="table-fn"}^
  Intratumoral MVD                                                           5.5±1.8                   5.0±1.7                   0.017^[b](#tfn3-etm-0-0-5087){ref-type="table-fn"}^
  peripheral thyroid parenchyma MVD                                          11.2±1.3                  11.6±1.1                  0.095
  MVD ratio of intratumoral/peripheral thyroid parenchyma (MVDR)             0.42±0.16                 0.48±0.17                 0.021^[b](#tfn3-etm-0-0-5087){ref-type="table-fn"}^

P\<0.01

P\<0.05. LMN+ group, PTC with LNM. LMN- group, PTC without LNM. CEUS, contrast-enhanced ultrasonography; MVD, microvascular density; PTC, papillary thyroid carcinoma; LNM, lymph node metastasis.
